iOnctura announces FDA clearance of IND application for roginolisib, a first-in-class allosteric modulator of PI3Kδ

Roginolisib is in development for solid and hematologic malignancies including uveal melanoma GENEVA and AMSTERDAM, Oct. 31, 2023 /PRNewswire/ — iOnctura, a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumor survival…